Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 24th 2022

touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications.

Questions

  1. Could you give us a brief overview of the health burden of Crohn’s disease and colitis? (0:10)
  2. What therapies are available to help manage symptoms of Crohn’s and colitis? (1:44)

Disclosures: Gil Melmed discloses consulting for Abbvie, Arena, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Genetech, Pfizer, Samsung Bioepis, Takeda, Shionogi, Prometheus Labs, Techlab, Fresenius Kabi, and Amgen; and receiving grant/ research support from Pfizer.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

To find out more visit our gastroenterology content here.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup